Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
NCT02040298
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG:
Clemastine
DRUG:
Placebo
Sponsor
University of California, San Francisco